Is GTx-104 Set To Replace Oral Nimodipine In Treating Aneurysmal Subarachnoid Hemorrhage?

Aneurysmal subarachnoid hemorrhage is a relatively uncommon type of stroke that accounts for about 5% of all strokes and an estimated 42,500 U.S. hospital-treated patients. It refers to bleeding over the surface of the brain in the subarachnoid space between the brain and the skull, which contains blood vessels that supply the brain. A primary cause of such bleeding is the rupture of an aneurysm in the brain.

Nimodipine is the established standard of care (SoC) for the management of aneurysmal subarachnoid hemorrhage (aSAH) and is clinically de-risked. Nonetheless, substantial unmet needs persist with its only available oral form.

Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe Now
Already subscribed? Sign in

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com